Tsilya Bass, MD
Psychiatry · West Hollywood, CANPI 1841330800
Payments from drug & device makers
Across 818 payments — averaging $90.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$52K
- Sunovion Pharmaceuticals Inc.$9K
- Takeda Pharmaceuticals U.S.A., Inc.$4K
- Eisai Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Avanir Pharmaceuticals, Inc.$861
- plus $5K from 22 others
What the payments were for
- Speaking & faculty fees$59,94581%
- Travel & lodging$3160%
- Food & beverage$13,40618%
- Education$850%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 254 | $52,290 |
| Sunovion Pharmaceuticals Inc. | 41 | $8,742 |
| Takeda Pharmaceuticals U.S.A., Inc. | 72 | $3,716 |
| Eisai Inc. | 35 | $1,813 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 51 | $1,019 |
| Avanir Pharmaceuticals, Inc. | 47 | $861 |
| Alkermes, Inc. | 50 | $848 |
| Otsuka America Pharmaceutical, Inc. | 54 | $724 |
| Lundbeck LLC | 38 | $634 |
| Vanda Pharmaceuticals Inc. | 31 | $621 |
| Almatica Pharma LLC | 32 | $612 |
| Axsome Therapeutics, Inc. | 23 | $386 |
| Neurocrine Biosciences, Inc. | 15 | $247 |
| Biohaven Pharmaceutical Holding Company Ltd. | 19 | $212 |
| Idorsia Pharmaceuticals US Inc | 11 | $190 |
| Bausch Health US, LLC | 9 | $166 |
| E.r. Squibb & Sons, L.L.C. | 9 | $158 |
| Merck | 7 | $120 |
| Teva Pharmaceuticals USA, Inc. | 6 | $114 |
| Johnson & Johnson | 3 | $60 |
| Corium, LLC | 2 | $53 |
| Biohaven Pharmaceuticals, Inc. | 2 | $41 |
| Pfizer | 2 | $36 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $25 |
| UCB, Inc. | 1 | $19 |
| Redhill Biopharma Inc. | 1 | $18 |
| Tonix Medicines, Inc. | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$49,132
- LATUDA$8,470
- TRINTELLIX$2,640
- Dayvigo$1,500
How this compares
$73,753 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrintellixVortioxetine Hydrobromide | 2,693 | $1,299,786 |
| VraylarCariprazine Hcl | 527 | $771,535 |
| Memantine Hcl ErMemantine Hcl | 3,214 | $302,231 |
| NamzaricMemantine Hcl/Donepezil Hcl | 496 | $295,128 |
| RexultiBrexpiprazole | 170 | $245,357 |
| Nurtec OdtRimegepant Sulfate | 151 | $149,718 |
| IngrezzaValbenazine Tosylate | 16 | $132,419 |
| DayvigoLemborexant | 369 | $122,045 |
| Rivastigmine | 773 | $118,780 |
| NuedextaDextromethorphan Hbr/Quinidine | 67 | $102,625 |
| BelsomraSuvorexant | 202 | $86,417 |
| Ramelteon | 601 | $74,632 |
| Doxepin Hcl | 340 | $60,000 |
| Donepezil Hcl | 3,587 | $49,579 |
| NeuproRotigotine | 59 | $47,611 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $3,716 | $1,299,7862,693 claims |
| AbbVieVraylar, Namzaric, Ubrelvy | $52,290 | $1,091,1251,047 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $724 | $245,357170 claims |
| PfizerNurtec Odt | $36 | $149,718151 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $247 | $132,41916 claims |
| Eisai Inc.Dayvigo | $1,813 | $122,045369 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $861 | $102,62567 claims |
| MerckBelsomra | $120 | $86,417202 claims |
| UCB, Inc.Neupro | $19 | $47,61159 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,019 | $35,67022 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $190 | $34,33870 claims |
| Axsome Therapeutics, Inc.Auvelity | $386 | $31,40456 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,954 psychiatry providers in California.
Other psychiatry in West Hollywood
- Elly LeeIrvine$49.8M
- Daniel ChuehOrange$17.9M
- Eric ChavezSan Diego$15.5M
- Lara ShirikjianTorrance$12.6M
- John DuffySanta Ana$12M
- Marina BusselPlaya Vista$12M
- Sherry SoefjeOceanside$11.9M
- Steven MacinaHuntington Beach$11.1M
- Wakelin McNeelRosemead$11M
- Donald AndersonBanning$10.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.